Status:
RECRUITING
Collection of Biological Samples From Patients Treated With CAR-T Cells for Hematological Malignancies
Lead Sponsor:
University Hospital, Montpellier
Conditions:
Lymphoma and Acute Lymphoblastic Leukemia
Eligibility:
All Genders
18+ years
Brief Summary
Development of CAR-T cell against CD19 B lymphoma and Acute Lymphoblastic Leukemia leaded to 2 authorized medication: Yescarta and Kymriah. Despite impressive outcomes in 3 phase II studies, never met...
Detailed Description
Development of CAR-T cell against CD19 B lymphoma and Acute Lymphoblastic Leukema leaded to 2 authorized medication: Yescarta and Kymriah. Despite impressive outcomes in 3 phase II studies, never met ...
Eligibility Criteria
Inclusion
- patient treated by CAR-T cell at the University Hospital of Montpellier
Exclusion
- refusal to sign consent form
- pregnant woman
- major protected
Key Trial Info
Start Date :
March 27 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 27 2040
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04290000
Start Date
March 27 2020
End Date
March 27 2040
Last Update
July 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Département d'hématologie clinique
Montpellier, France, 34295